$\square$ 

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

L									
OMB Number: 3235-0287									
Estimated average burden									
hours per response:	0.5								

(Spouse Trust)

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [ APLS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Machiels Alec				X Director 10% Owner					
,			—	Officer (give title Other (specify					
(Last) (First) (Middle)		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/15/2022	below) below)					
C/O APELLIS PHARMACEUTICALS, INC.			08/13/2022						
100 FIFTH AVENUE, 3RD FLOOR		TOOR							
		LOOK	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)				X Form filed by One Reporting Person					
WALTHAM	MA	02451	_	Form filed by More than One Reporting Person					
(City)	(State)	(Zip)							

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	08/15/2022		<b>M</b> <sup>(1)</sup>		1,250	Α	\$2.67	265,024	D	
Common Stock	08/15/2022		<b>S</b> <sup>(1)</sup>		1,250	D	\$67.21	263,774	D	
Common Stock								250,000	I	Indirect Owner (Bauhaus 1 LLC)
Common Stock								11,950	I	Indirect Owner (Owned by Spouse) <sup>(2)</sup>
Common Stock								150,000	I	Indirect Owner (Spouse

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$2.67	08/15/2022		M <sup>(1)</sup>			1,250	(3)	12/04/2023	Common Stock	1,250	\$0	118,529	D	

Explanation of Responses:

1. This is a scheduled exercise and sale from 10B5-1 trading plan.

2. Owned by spouse.

3. This option was granted on December 5, 2013 and fully vested.

/s/ David Watson, attorney-in-08/16/2022

fact for Alec Machiels

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.